37 related articles for article (PubMed ID: 16673210)
1. Effects of Hormones on Breast Development and Breast Cancer Risk in Transgender Women.
Berliere M; Coche M; Lacroix C; Riggi J; Coyette M; Coulie J; Galant C; Fellah L; Leconte I; Maiter D; Duhoux FP; François A
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612241
[TBL] [Abstract][Full Text] [Related]
2. Changes in Serum Testosterone and Adrenal Androgen Levels in Transgender Women With and Without Gonadectomy.
Collet S; Gieles NC; Wiepjes CM; Heijboer AC; Reyns T; Fiers T; Lapauw B; den Heijer M; T'Sjoen G
J Clin Endocrinol Metab; 2023 Jan; 108(2):331-338. PubMed ID: 36201493
[TBL] [Abstract][Full Text] [Related]
3. Alteration of ACTH and Cortisol Levels After Estradiol Valerate Treatment in a Male Subject With Gender Dysphoria: A Case Report.
Anno T; Kawasaki F; Shigemoto R; Irie S; Mune T; Kaku K; Kaneto H
Front Endocrinol (Lausanne); 2019; 10():751. PubMed ID: 31827460
[No Abstract] [Full Text] [Related]
4. Effects on the endocrine system of long-term treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia.
Eri LM; Haug E; Tveter KJ
Scand J Clin Lab Invest; 1996 Jul; 56(4):319-25. PubMed ID: 8837238
[TBL] [Abstract][Full Text] [Related]
5. Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist.
Dittrich R; Binder H; Cupisti S; Hoffmann I; Beckmann MW; Mueller A
Exp Clin Endocrinol Diabetes; 2005 Dec; 113(10):586-92. PubMed ID: 16320157
[TBL] [Abstract][Full Text] [Related]
6. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
[TBL] [Abstract][Full Text] [Related]
7. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
8. High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone.
Mueller A; Dittrich R; Binder H; Kuehnel W; Maltaris T; Hoffmann I; Beckmann MW
Eur J Endocrinol; 2005 Jul; 153(1):107-13. PubMed ID: 15994752
[TBL] [Abstract][Full Text] [Related]
9. Effects on the male endocrine system of long-term treatment with gonadotropin-releasing hormone agonists and estrogens in male-to-female transsexuals.
Mueller A; Binder H; Cupisti S; Hoffmann I; Beckmann MW; Dittrich R
Horm Metab Res; 2006 Mar; 38(3):183-7. PubMed ID: 16673210
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience.
Gooren LJ; Giltay EJ; Bunck MC
J Clin Endocrinol Metab; 2008 Jan; 93(1):19-25. PubMed ID: 17986639
[TBL] [Abstract][Full Text] [Related]
11. Drug treatment of paraphilic and nonparaphilic sexual disorders.
Guay DR
Clin Ther; 2009 Jan; 31(1):1-31. PubMed ID: 19243704
[TBL] [Abstract][Full Text] [Related]
12. Control of prostate growth.
Coffey DS; Isaacs JT
Urology; 1981 Mar; 17(Suppl 3):17-24. PubMed ID: 6163242
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
